HC Wainwright & Co. Initiates Coverage On CG Oncology with Buy Rating, Announces Price Target of $75
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Andres Maldonado initiates coverage on CG Oncology (NASDAQ:CGON) with a Buy rating and a price target of $75.
February 14, 2024 | 11:55 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
CG Oncology receives a Buy rating and a $75 price target from HC Wainwright & Co., indicating a positive outlook on the stock.
The initiation of coverage by a reputable analyst firm like HC Wainwright & Co. with a Buy rating and a significant price target suggests a strong bullish outlook for CG Oncology. This can lead to increased investor interest and potentially drive the stock price up in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100